Add a Comment By Media Staff   |  Thursday, April 4, 2013 Early research led by investigators at Memorial Sloan-Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Visit site:
Combining Two FDA-Approved Drugs May Be Harmful for Patients with Metastatic Melanoma